Summary not available.
PsyBio Therapeutics Corp. (TSXV: PSYB, OTCQB: PSYBF) will be presenting at the KCSA Psychedelics Investor Conference on October 14th at 10:30 a.m. ET. The conference aims to showcase innovative biotechnology focused on developing psycho-targeted therapeutics for mental health improvement. Interested participants can register here. PsyBio's expertise lies in drug discovery through synthetic biology and metabolic engineering, utilizing psychoactive compounds derived from hallucinogenic mushrooms to develop novel therapies.
PsyBio Therapeutics Corp. (OTCQB: PSYBF) announced the commencement of trading of its subordinate voting shares on the OTCQB Venture Market on July 14, 2021. This listing aims to increase visibility among U.S. investors and enhance liquidity for shareholders. The company is also applying for DTC eligibility, which will facilitate electronic settlement of stock transfers, making it easier for investors. PsyBio continues to trade on the TSX Venture Exchange as PSYB and on the Frankfurt Stock Exchange as PSYB.F.